Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26048394 | 0.92 | DNM1 (0.44) | CA12CA1LMNAALDH1A1KDM5A | |
| SCHEMBL8358850 | 0.92 | PAOX (0.47) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL31050952 | 0.92 | DNM1 (0.44) | CA12CA1LMNAALDH1A1KDM5A | |
| Hydrochloric Acid SCHEMBL8355063 | 0.90 | DNM1 (0.46) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL9820372 | 0.89 | ALDH1A1 (0.55) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL8360172 | 0.89 | ACHE (0.48) | ALDH1A1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL6156406 | 0.88 | CES2 (0.45) | CA12CA1ALDH1A1TSHRKMT2A | |
| SCHEMBL17645573 | 0.88 | CES2 (0.45) | CA12CA1ALDH1A1TSHRKMT2A | |
| SCHEMBL14543500 | 0.88 | MMP1 (0.46) | MMP1MMP2MMP3MMP8CA12 | |
| Hydrochloric Acid SCHEMBL8356534 | 0.87 | DNM1 (0.48) | ALDH1A1HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119836414-A | Lipids for lipid nanoparticle formulations | 爱康泰生治疗公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240270679-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2024-08-15 | — | — | US | disclosed |
| EP-4410317-A2 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2024-08-07 | — | — | EP | disclosed |
| US-20240122854-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-04-18 | — | — | US | disclosed |
| EP-3615510-B1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024054843-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-03-14 | — | — | WO | disclosed |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-11-21 | — | — | US | disclosed |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-11-21 | — | — | US | disclosed |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-11-21 | — | — | US | disclosed |
| CN-116693411-A | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-110799492-B | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids | 爱康泰生治疗公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2022-03-17 | — | — | US | disclosed |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2022-03-17 | — | — | US | disclosed |
| EP-3615510-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200943-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018191719-A1 | LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Acuitas Therapeutics, Inc. (CA) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270679-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | LIPA, LIPC, LDLR | MMP1 3799/4885MMP2 3715/4885MMP3 2092/4885 |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | TTPA, ACAA2, CPT2 | MMP1 3912/4885MMP2 3243/4885MMP3 2576/4885 |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | TTPA, ACAA2, POLRMT | MMP1 4124/4885MMP2 3498/4885MMP3 2799/4885 |
| US-20240122854-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | LMNB1, TTPA, ACAA2 | MMP1 3940/4885MMP2 3622/4885MMP3 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.